alzheon, Author at Alzheon | Preserving Future Memories - Page 5 of 21

About alzheon

This author has not yet filled in any details.
So far alzheon has created 202 blog entries.

28 Apr, 2023

AAN 2023: ALZ-801 for Alzheimer’s found to improve cognition in trial

alzheon2023-05-03T11:24:17-04:00April 28th, 2023|

28 Apr, 2023

Oral Anti-Amyloid Shows Disease-Modifying Potential: Phase 2 Data

alzheon2023-05-03T12:05:29-04:00April 28th, 2023|

18 Apr, 2023

Alzheon to Present Baseline Imaging Characteristics from Ongoing APOLLOE4 Phase 3 Trial of Oral Tablet ALZ-801 (Valiltramiprosate) and Results of Phase 2 Biomarker Study at American Academy of Neurology Conference in Boston

alzheon2024-08-12T09:50:32-04:00April 18th, 2023|

22 Mar, 2023

Alzheon to Present Biomarker, Brain Preservation and Clinical Effects of Oral Tablet ALZ-801 (Valiltramiprosate) at Upcoming AD/PD 2023 Conference in Gothenburg, Sweden

alzheon2024-08-12T09:51:50-04:00March 22nd, 2023|

20 Mar, 2023

The New Era of Life Sciences

alzheon2024-08-02T09:47:38-04:00March 20th, 2023|

12 Mar, 2023

Why lecanemab’s success spells the revival of small-molecule Alzheimer’s treatments

alzheon2024-05-15T16:38:27-04:00March 12th, 2023|

21 Feb, 2023

Newsweek Investment Report: Interview with Dr. Martin Tolar, President & CEO of Alzheon, Inc.

alzheon2023-04-16T12:18:58-04:00February 21st, 2023|

17 Feb, 2023

‘It’s night and day’: Biogen’s new Alzheimer’s drug may spur more investment in fighting the disease

alzheon2024-08-02T08:55:07-04:00February 17th, 2023|

15 Feb, 2023

I interview Dr. Martin Tolar, Founder, CEO and President of Alzheon on the Phase 3 trial going on right now

alzheon2023-02-16T12:37:20-05:00February 15th, 2023|

20 Jan, 2023

Biotech and Business Development Leader Wendy Nelson on Living With the APOE4 Gene

alzheon2023-01-20T11:31:56-05:00January 20th, 2023|